Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 19/20 | 0.85 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.67 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5575936 | 1.00 | CHRM3 (0.85) | CHRM3CHRM1CHRM2 | |
| Trifluoroacetic Acid SCHEMBL5525864 | 0.98 | CHRM3 (0.81) | CHRM3CHRM1CHRM2 | |
| SCHEMBL14435017 | 0.93 | CHRM3 (0.98) | CHRM3CHRM1 | |
| Trifluoroacetic Acid SCHEMBL5525503 | 0.86 | CHRM3 (0.64) | CHRM3CHRM1CHRM2 | |
| Trifluoroacetic Acid SCHEMBL5525505 | 0.84 | CHRM3 (0.62) | CHRM3CHRM1CHRM2 | |
| Trifluoroacetic Acid SCHEMBL4098047 | 0.84 | CHRM3 (0.88) | CHRM3CHRM1 | |
| Trifluoroacetic Acid SCHEMBL5522157 | 0.83 | CHRM3 (0.59) | CHRM3CHRM1 | |
| Trifluoroacetic Acid SCHEMBL4103650 | 0.83 | CHRM3 (0.88) | CHRM3CHRM1 | |
| Trifluoroacetic Acid SCHEMBL5523160 | 0.83 | CHRM3 (0.68) | CHRM3CHRM1CHRM2 | |
| Trifluoroacetic Acid SCHEMBL5576968 | 0.83 | CHRM3 (0.68) | CHRM3CHRM1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179131-A1 | Novel M3 Muscarinic Acetylcholine Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2007-08-02 | — | — | US | claimed |
| US-20070179131-A1 | Novel M3 Muscarinic Acetylcholine Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179131-A1 | Novel M3 Muscarinic Acetylcholine Receptor Antagonists | CHRM3, CHRM2, CHRNA3 | CHRM3 1/4885CHRM1 8/4885CHRM2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.